Bio Implants Market Scope And Analysis

  • Report Code : TIPHE100001101
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Bio-Implants Market Scope, Analysis, and Trends by 2031

Buy Now


Bio-Implants Market Report Scope

Report Attribute Details
Market size in 2023 US$ 117.82 Billion
Market Size by 2031 US$ 223.06 Billion
Global CAGR (2023 - 2031) 8.3%
Historical Data 2021-2023
Forecast period 2023-2031
Segments Covered By Type
  • Cardiovascular Implants
  • Orthopedic Implants
  • Dental Implants
  • Ophthalmic Implants
By Material
  • Metals
  • Ceramics
  • Polymers
By and End User
  • Hospitals & Clinics and Ambulatory Surgical Centers
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • LifeNet Health
  • Smith Nephew
  • Arthrex Inc
  • Clinic Lemanic
  • Alpha Bio Tec
  • MiMedx Group
  • Medtronic
  • St Jude Medical Abbott
  • Stryker Cooperation
  • Key Player Analysis:

    LifeNet Health; Smith & Nephew; Arthrex, Inc.; Clinic Lemanic; Alpha Bio Tec; MiMedx Group; Medtronic; St Jude Medical (Abbott); Stryker Cooperation; DePuy Synthes; Biomet (Zimmer); Exactech, Inc.; Cochlear Ltd; and Straumann AG are among the key players profiled in the bio-implants market report.

    Recent Developments:

    Companies operating in the market adopt such as mergers and acquisitions. As per the company press releases, below are a few recent key developments:

    • In February 2023, CurvaFix, Inc., a medical device developer designed to repair fractures in curved bones, announced the launch of its smaller diameter 7.5mm—CurvaFix IM implant. It is designed to simplify surgical procedures and provide strong, stable fixation in small bones and is intended to enable patients with bones.
    • In June 2022, ZimVie launched the Food and Drug Administration, approved T3 pro-engineered implants, and Encode Emergence Healing Abutment in the US.
    • In June 2021, Intelligent Implants Ltd., a medical device company, was granted a breakthrough by the US FDA for SmartFuse, an orthopedic implant technology. The SmartFuse platform was designed to remotely stimulate, control, and monitor bone growth to make real-time clinical decisions. The product is indicated for first-use patients undergoing lumbar spinal fusion.
    • In February 2021, Medtronic launched the TYRX Absorbable Antibacterial Sheath, an absorbable, disposable, antibacterial sheath designed for stabilizing a cardiac implantable electronic device or implanted neurostimulator.